BSE · 544409
Astonea Labs Limited
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹148 Cr with net profit ₹5 Cr — a 3.05% net margin, versus 5.48% the period before.
Shareholding
As of 2026-03-31
- Promoter72.3%
- Public27.63%
- DII0.07%
376 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.55× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ESM · ESM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs · ranked #1 of 30 by market cap · medians across 26 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Divis Laboratories Ltd. | ₹2,07,995 Cr | 276.76 | 12.39 | 15.32% | 24.32% |
| Acutaas Chemicals Limited | ₹26,475 Cr | 200.98 | 16.01 | 21.54% | 26.6% |
| Neuland Laboratories Ltd. | ₹24,636 Cr | 68.22 | 13.15 | 19.42% | 17.99% |
| Jubilant Pharmova Ltd. | ₹15,317 Cr | 127.37 | 2.14 | 5.62% | 4.84% |
| Aarti Drugs Ltd. | ₹3,768 Cr | 68.23 | 2.43 | 12.58% | 7.6% |
| SMS Pharmaceuticals Ltd. | ₹3,509 Cr | 34.4 | 4.47 | 12.98% | 11.5% |
| Hikal Limited | ₹2,676 Cr | 185.46 | 2.24 | 3.03% | -2.88% |
| Beta Drugs Limited | ₹2,234 Cr | 246.74 | 9.13 | 16.95% | 10.78% |
| NGL Fine Chem Limited | ₹2,026 Cr | 42.12 | 6.16 | 14.62% | 9.59% |
| Fermenta Biotech Ltd. | ₹1,370 Cr | 69.88 | 3.29 | 17.67% | 13.66% |
| Astonea Labs Limited(this company) | — | — | — | — | — |
AI analysis
AI-generated · google/gemini-2.5-flashAstonea Labs Limited reported revenue of Rs 97.71 Cr for the most recent fiscal year. The company's market activities are currently under an Enhanced Surveillance Measure (ESM) Stage 2.
Positives
- +Revenue increased from Rs 30.17 Cr in March 2022 to Rs 97.71 Cr in March 2025.
- +Net profit grew from Rs 0.2488 Cr in March 2022 to Rs 5.3505 Cr in March 2025.
- +EPS rose from Rs 0.33 in March 2022 to Rs 6.94 in March 2025.
- +Promoter holding is 72.3049% as of March 2026.
- +No promoter shares are reported as pledged.
Negatives
- −The debt-to-equity ratio of 3.16 is high.
- −The company is under ESM Stage 2 surveillance.
- −Promoter holding decreased from 98.4325% in August 2024 to 72.3049% in March 2026.
- −Institutional (DII + FII) holding decreased from 12.5583% in June 2025 to 0.0666% in March 2026.
- −No quarterly financial results are disclosed in the provided data.
Financial performance
Astonea Labs Limited's revenue increased from Rs 30.17 Cr in March 2022 to Rs 97.71 Cr in March 2025. Net profit also rose from Rs 0.2488 Cr in March 2022 to Rs 5.3505 Cr in March 2025. Earnings per share (EPS) grew from Rs 0.33 in March 2022 to Rs 6.94 in March 2025.
Profitability & returns
The company's net profit reached Rs 5.3505 Cr in March 2025, up from Rs 0.2488 Cr in March 2022. EBITDA has shown an upward trend, from Rs 2.0806 Cr in March 2022 to Rs 10.7271 Cr in March 2025.
Balance sheet
As of the most recent data, Astonea Labs Limited has a debt-to-equity ratio of 3.16. No other balance sheet specific figures are available.
Ownership & pledges
Promoter holding in Astonea Labs Limited is 72.3049% as of March 2026. Public shareholding stands at 27.6285%, and institutional holding (DII and FII combined) is 0.0666%. There are no promoter pledges reported.
Regulatory & surveillance
Astonea Labs Limited is currently under Enhanced Surveillance Measure (ESM) Stage 2, indicating heightened scrutiny of its trading activities.
Data as of — price: 2026-07-30 · financials: Mar 26 · shareholding: Mar 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.